Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Authors:
Top Cited Papers
- 3 March 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (583)
Abstract
Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.Keywords
Funding Information
- National Institutes of Health (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085453, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, UC4 DK106993, UC4 DK11700901, U01 DK 106693-02, UM1AI109565)
- National Institutes of Health (UM1AI109565)
- National Institutes of Health
- Juvenile Diabetes Research Foundation International
- JDRF (U01 DK061034)
- JDRF (U01 DK085466)
- JDRF (U01 DK085476)
- JDRF (U01 DK107014)
- JDRF (UC4 DK11700901)
- JDRF (106693)
- JDRF (2019-833-S-B)
- JDRF
This publication has 66 references indexed in Scilit:
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD MiceDiabetes, 2011
- Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching MethodPLOS ONE, 2010
- Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of OnsetDiabetes, 2009
- Preservation of β-Cell Function in Autoantibody-Positive Youth With DiabetesDiabetes Care, 2009
- Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1Diabetes Care, 2009
- C‐peptide in the natural history of type 1 diabetesDiabetes/Metabolism Research and Reviews, 2009
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.Journal of Clinical Investigation, 1986